Literature DB >> 29643251

Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease.

Jenny V Tobin1, Daniel P Zimmer2, Courtney Shea2, Peter Germano2, Sylvie G Bernier2, Guang Liu2, Kim Long2, Joy Miyashiro2, Sheila Ranganath2, Sarah Jacobson2, Kim Tang2, G-Yoon Jamie Im2, James Sheppeck2, Joel D Moore2, Kristine Sykes2, James Wakefield2, Renee Sarno2, Ali R Banijamali2, Albert T Profy2, G Todd Milne2, Mark G Currie2, Jaime L Masferrer2.   

Abstract

Soluble guanylate cyclase (sGC), a key signal-transduction enzyme, increases the conversion of guanosine-5'-triphosphate to cGMP upon binding of nitric oxide (NO). Endothelial dysfunction and/or reduced NO signaling have been implicated in cardiovascular disease pathogenesis and complications of diabetes and have been associated with other disease states and aging. Soluble guanylate cyclase (sGC) stimulators are small-molecule drugs that bind sGC and enhance NO-mediated cGMP signaling. The pharmacological characterization of IW-1973 [1,1,1,3,3,3-hexafluoro-2-(((5-fluoro-2-(1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazol-3-yl) pyrimidin-4-yl)amino)methyl)propan-2-ol], a novel clinical-stage sGC stimulator under clinical investigation for treatment of heart failure with preserved ejection fraction and diabetic nephropathy, is described. In the presence of NO, IW-1973 stimulated sGC in a human purified enzyme assay and a HEK-293 whole cell assay. sGC stimulation by IW-1973 in cells was associated with increased phosphorylation of vasodilator-stimulated phosphoprotein. IW-1973, at doses of 1-10 mg/kg, significantly lowered blood pressure in normotensive and spontaneously hypertensive rats. In a Dahl salt-sensitive hypertension model, IW-1973 significantly reduced blood pressure, inflammatory cytokine levels, and renal disease markers, including proteinuria and renal fibrotic gene expression. The results were affirmed in mouse lipopolysaccharide-induced inflammation and rat unilateral ureteral obstruction renal fibrosis models. A quantitative whole-body autoradiography study of IW-1973 revealed extensive tissue distribution and pharmacokinetic studies showed a large volume of distribution and a profile consistent with predicted once-a-day dosing in humans. In summary, IW-1973 is a potent, orally available sGC stimulator that exhibits renoprotective, anti-inflammatory, and antifibrotic effects in nonclinical models.
Copyright © 2018 The Author(s).

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29643251     DOI: 10.1124/jpet.117.247429

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

1.  Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial.

Authors:  James E Udelson; Gregory D Lewis; Sanjiv J Shah; Michael R Zile; Margaret M Redfield; John Burnett; John Parker; Jelena P Seferovic; Phebe Wilson; Robert S Mittleman; Albert T Profy; Marvin A Konstam
Journal:  JAMA       Date:  2020-10-20       Impact factor: 56.272

2.  Soluble Guanylate Cyclase Stimulators and Activators.

Authors:  Peter Sandner; Daniel P Zimmer; G Todd Milne; Markus Follmann; Adrian Hobbs; Johannes-Peter Stasch
Journal:  Handb Exp Pharmacol       Date:  2021

3.  Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.

Authors:  John P Hanrahan; Ian H de Boer; George L Bakris; Phebe J Wilson; James D Wakefield; Jelena P Seferovic; Jennifer G Chickering; Yueh-Tyng Chien; Kenneth Carlson; Michael D Cressman; Mark G Currie; G Todd Milne; Albert T Profy
Journal:  Clin J Am Soc Nephrol       Date:  2020-12-16       Impact factor: 8.237

4.  Solution structures of the Shewanella woodyi H-NOX protein in the presence and absence of soluble guanylyl cyclase stimulator IWP-051.

Authors:  Cheng-Yu Chen; Woonghee Lee; Paul A Renhowe; Joon Jung; William R Montfort
Journal:  Protein Sci       Date:  2020-12-10       Impact factor: 6.993

5.  sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH.

Authors:  Katherine C Hall; Sylvie G Bernier; Sarah Jacobson; Guang Liu; Ping Y Zhang; Renee Sarno; Victoria Catanzano; Mark G Currie; Jaime L Masferrer
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-13       Impact factor: 11.205

6.  Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease.

Authors:  Daniel P Zimmer; Courtney M Shea; Jenny V Tobin; Boris Tchernychev; Peter Germano; Kristie Sykes; Ali R Banijamali; Sarah Jacobson; Sylvie G Bernier; Renee Sarno; Andrew Carvalho; Yueh-Tyng Chien; Regina Graul; Emmanuel S Buys; Juli E Jones; James D Wakefield; Gavrielle M Price; Jennifer G Chickering; G Todd Milne; Mark G Currie; Jaime L Masferrer
Journal:  Front Pharmacol       Date:  2020-04-08       Impact factor: 5.810

7.  Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical-stage soluble guanylate cyclase stimulator in rats.

Authors:  Ali R Banijamali; Andrew E Carvalho; James D Wakefield; Peter Germano; Timothy C Barden; Jenny V Tobin; Daniel P Zimmer; Jaime L Masferrer; Albert T Profy; Mark G Currie; G Todd Milne
Journal:  Pharmacol Res Perspect       Date:  2020-04

8.  An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension.

Authors:  John P Hanrahan; Jelena P Seferovic; James D Wakefield; Phebe J Wilson; Jennifer G Chickering; Joon Jung; Kenneth E Carlson; Daniel P Zimmer; Andrew L Frelinger; Alan D Michelson; Linda Morrow; Michael Hall; Mark G Currie; G Todd Milne; Albert T Profy
Journal:  Diabetologia       Date:  2019-12-19       Impact factor: 10.122

Review 9.  Sickle cell disease: progress towards combination drug therapy.

Authors:  Betty S Pace; Athena Starlard-Davenport; Abdullah Kutlar
Journal:  Br J Haematol       Date:  2021-01-20       Impact factor: 6.998

Review 10.  The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective.

Authors:  Shalini M Krishnan; Jan R Kraehling; Frank Eitner; Agnès Bénardeau; Peter Sandner
Journal:  Int J Mol Sci       Date:  2018-06-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.